ProCE Banner Activity

Experts Answer Frequently Asked Questions on the Management of Myeloproliferative Neoplasms

Clinical Thought
Read expert answers to key questions from the audience at a recent symposium on optimal management of patients with myeloproliferative neoplasms.

Released: January 16, 2020

Expiration: January 14, 2021

No longer available for credit.

Share

Faculty

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Alessandro M. Vannucchi

Alessandro M. Vannucchi, MD

Full Professor of Hematology
Department of Experimental and Clinical Medicine
University of Florence
Director
Center of Research and Innovation of Myeloproliferative Neoplasms
AOU Careggi
Florence, Italy

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Celgene

CTI BioPharma Corp

Geron

Program Director Disclosure

Program Director

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received consulting fees from Celgene, Constellation, Incyte, Novartis, Pragmatist, and Sierra and funds for research support from Blueprint Medicines, Celgene, CTI BioPharma, Genentech, Gilead Sciences, Incyte, Novartis, NS Pharma, Promedior, and Roche.

Faculty Disclosure

Primary Author

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit K. Rampal, MD, PhD, has disclosed that he has received consulting fees from Beyond Spring, Celgene, Constellation, Jazz, Partner Therapeutics, and Stemline and funds for research support from Constellation and Stemline.

Alessandro M. Vannucchi, MD

Full Professor of Hematology
Department of Experimental and Clinical Medicine
University of Florence
Director
Center of Research and Innovation of Myeloproliferative Neoplasms
AOU Careggi
Florence, Italy

Alessandro M. Vannucchi, MD, disclosed that he has received consulting fees from Incyte and Novartis and fees for non-CME/CE services from Celgene.